Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; SCORCH (Single Cell Opioid Responses in the Context of HIV) Program: Data Coordination, Analysis, and Scientific Outreach; Data Mining and Functional Validation.                    

*Date:*                         November 15, 2024.                    

*Time:*                         10:00 a.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Caitlin Elizabeth Angela Moyer, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577,                         *caitlin.moyer@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services.                    

*Date:*                         November 15, 2024.                    

*Time:*                         12:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Trinh T. Tran, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843,                         *trinh.tran@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; NIH Support for Conferences and Scientific Meetings.                    

*Date:*                         November 19, 2024.                    

*Time:*                         1:30 p.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Li Rebekah Feng, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-7245,                         *rebekah.feng@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA).                    

*Date:*                         November 21, 2024.                    

*Time:*                         10:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Sheila Pirooznia, Ph.D., Scientific Review Officer, Division of Extramural Review, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 496-9350,                         *sheila.pirooznia@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse, Special Emphasis Panel; NIDA Avant-Garde Program for HIV and Substance Use Disorder Research; NIDA Avenir Award Program for HIV and Substance Use Disorder Research.                    

*Date:*                         December 9, 2024.                    

*Time:*                         9:30 a.m. to 6:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Sheila Pirooznia, Ph.D., Scientific Review Officer, Division of Extramural Review, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 496-9350,                         *sheila.pirooznia@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; NIDA Avant-Garde Program for HIV and Substance Use Disorder Research; NIDA Avenir Award Program for HIV and Substance Use Disorder Research.                    

*Date:*                         December 12, 2024.                    

*Time:*                         9:30 a.m. to 6:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Address:*                         National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.                    

*Meeting Format:*                         Virtual Meeting.                    

*Contact Person:*                         Sheila Pirooznia, Ph.D., Scientific Review Officer, Division of Extramural Review, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 496-9350,                         *sheila.pirooznia@nih.gov.*

                        (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research                               ( print page 81923)                            Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)                    

Dated: October 3, 2024.

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-23322 Filed 10-8-24; 8:45 am]

BILLING CODE 4140-01-P